{
  "acquisition_date": "2026-01-22",
  "source": "European Urology Oncology 2024 - PMC11162506",
  "title": "Co-occurring BRCA2/SPOP Mutations Predict Exceptional PARP Inhibitor Sensitivity in mCRPC",
  "files_acquired": [
    "NIHMS1949149-supplement-1.docx",
    "NIHMS1949149-supplement-2.xlsx",
    "NIHMS1949149-supplement-2 (3).xlsx",
    "NIHMS1949149-supplement-2 (1).xlsx",
    "NIHMS1949149-supplement-2 (2).xlsx"
  ],
  "dataset_summary": {
    "total_patients": 131,
    "brca2_spop_co_mutation": 14,
    "brca2_alone": 117,
    "parp_treatment": "100% (131/131)",
    "genetic_data": [
      "BR2 (germline/somatic, alteration types)",
      "SPOP",
      "TP53, PTEN, RB1, ATM, AR",
      "TMPRSS2 fusions"
    ],
    "outcomes": [
      "PSA50 response rate",
      "PSA progression-free survival",
      "Clinical/radiographic PFS",
      "Overall survival"
    ],
    "key_finding": "BRCA2/SPOP co-mutation: HR 0.16 (0.05-0.47), p=0.001"
  },
  "validation_readiness": {
    "mutations": "EXCELLENT",
    "treatment": "EXCELLENT (100% PARP)",
    "outcomes": "EXCELLENT (multiple metrics)",
    "sample_size": "EXCELLENT (131 patients, exceeds 50-patient target)",
    "overall": "\u2b50\u2b50\u2b50 EXCELLENT - EXCEEDS TARGET"
  },
  "next_steps": [
    "Extract patient-level data from Excel files (may need to check all sheets/files)",
    "Format mutations for SL pipeline (gene, variant, chrom, pos, ref, alt)",
    "Link mutations \u2192 treatment \u2192 outcomes",
    "Run SL pipeline validation",
    "Compare preo actual outcomes"
  ]
}